Continuous cardiac output and hemodynamic monitoring: high temporal correlation between plasma TNF-α and hemodynamic changes during a sepsis-like state in cancer immunotherapy

Through continuous cardiac output monitoring, we investigated the temporal relationship between hemodynamic changes and plasma cytokines in a cancer patient who developed collateral sepsis to immunotherapy. A 52-year-old male with metastatic renal cell carcinoma received interleukin-2 (IL-2) infusion completing 72 h of administration. The patient developed 3 sepsis-like states including systemic inflammatory response syndrome (SIRS), shock, and multiple organ dysfunction syndrome (MODS). Hemodynamic parameters including systemic vascular resistance index (SVRI), left ventricular stroke work index (LVSWI) and cardiac index (CI) were measured over 60 h. Peripheral blood was drawn when SVRI dropped 20% in the patient and plasma cytokines including TNF-α , IL-6 and IL-1β were measured using ELISA. After 60 h of immunotherapy, the patient showed a 63.4% decrease in SVRI, 54.5% decrease in LVSWI and 65.4% increase in CI. The evaluation of systemic cytokines revealed different kinetic patterns: (i) a sustained increase in TNFα levels through all 3 sepsis-like states; (ii) IL-6 increased preferentially during SIRS and shock, while up/down-responses were found during MODS; (iii) IL-1β was undetectable during the entire study period. A high temporal relationship between hemodynamic changes and plasma TNF-α, but not IL-6, was found. Although there are factors other than cytokines that can alter vascular resistance, this finding could represent an approach to evaluate the course of hemodynamia and probably the systemic cytokine expression after IL-2 administration in renal cancer.

[1]  F. Ognibene,et al.  Validation of continuous thermodilution cardiac output in critically ill patients with analysis of systematic errors. , 1998, Journal of critical care.

[2]  A. Ravaud,et al.  Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma , 1998 .

[3]  R. Ohta,et al.  Evaluation of a continuous cardiac output and mixed venous oxygen saturation catheter in critically ill surgical patients. , 1997, Critical care medicine.

[4]  J. Cavaillon,et al.  Presence of high levels of leukocyte-associated interleukin-8 upon cell activation and in patients with sepsis syndrome , 1997, Infection and immunity.

[5]  L. Brandt,et al.  [Hyperdynamic hemodynamics following high-dose interleukin 2-interferon alpha therapy in patients with metastatic renal cell carcinoma. Immunotherapy as a clinical sepsis model?]. , 1996, Der Anaesthesist.

[6]  A. Girbes,et al.  High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan. , 1996, Critical care medicine.

[7]  C. Sprung,et al.  Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. , 1995, Critical care medicine.

[8]  R. Motzer,et al.  Phase iii randomized trial of interleukin‐2 with or without lymphokine‐activated killer cells in the treatment of patients with advanced renal cell carcinoma , 1995, Cancer.

[9]  M. Haller,et al.  Evaluation of a new continuous thermodilution cardiac output monitor in cardiac surgical patients: a prospective criterion standard study. , 1995, Critical care medicine.

[10]  G. Hempelmann,et al.  Is continuous cardiac output measurement using thermodilution reliable in the critically ill patient? , 1994, Critical care medicine.

[11]  S. Rosenberg,et al.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. , 1994, JAMA.

[12]  F. Cerra,et al.  Multiple organ failure syndrome in the 1990s. Systemic inflammatory response and organ dysfunction. , 1994, JAMA.

[13]  E. Moore,et al.  Effects of accidental trauma on cytokine and endotoxin production. , 1993, Critical care medicine.

[14]  W. Shoemaker,et al.  Effects of accidental trauma on cytokine and endotoxin production , 1993, Critical care medicine.

[15]  R. Bone Guidelines for the Use of Innovative Therapies in Sepsis , 1993 .

[16]  J. Cavaillon,et al.  Circulating cytokines: the tip of the iceberg? , 1992, Circulatory shock.

[17]  J. Cavaillon,et al.  Dysregulation of in vitro cytokine production by monocytes during sepsis. , 1991, The Journal of clinical investigation.

[18]  J. Cavaillon,et al.  Dissociation between plasma and monocyte‐associated cytokines during sepsis , 1991, European journal of immunology.

[19]  J. Schellekens,et al.  Prognostic Values of Tumor Necrosis Factor/Cachectin, Interleukin-l, Interferon-α, and Interferon-γ in the Serum of Patients with Septic Shock , 1990 .

[20]  L. G. Thijs,et al.  Increased plasma levels of interleukin-6 in sepsis [see comments] , 1989 .

[21]  P. Brandtzaeg,et al.  The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome , 1989, The Journal of experimental medicine.

[22]  E. Girardin,et al.  Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. , 1988, The New England journal of medicine.

[23]  J. Sculier,et al.  Haemodynamic effects induced by intravenous administration of high doses of r-Met Hu IL-2 [ala-125] in patients with advanced cancer , 2005, Intensive Care Medicine.

[24]  R. Bone,et al.  Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. , 1996, Critical care medicine.

[25]  M. Haller,et al.  Evaluation of a new continuous thermodilution cardiac output monitor in critically ill patients: a prospective criterion standard study. , 1995, Critical care medicine.

[26]  R. Tompkins,et al.  Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. , 1990, The Journal of infectious diseases.

[27]  J. Schellekens,et al.  Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. , 1990, The Journal of infectious diseases.

[28]  L A Aarden,et al.  Increased plasma levels of interleukin-6 in sepsis. , 1989, Blood.

[29]  F. Ognibene,et al.  Cardiorespiratory effects of immunotherapy with interleukin-2. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  C. Dinarello Interleukin-1 and its biologically related cytokines. , 1989, Advances in immunology.

[31]  M. Karno,et al.  Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.